At least 28,187 plant species are recorded as medicinal, and only a small share carry the evidence a U.S. product needs. Fewer than 16% of medicinal plant species are cited in a regulatory publication. This course follows that gap through U.S. law and FDA data: identity, safety evidence, the new dietary ingredient rule, the drug route, patents and access.
Status. EUTECNIQ is a company in formation with no laboratory, data, customers or patents. This course teaches published facts, not legal advice.
28,187plant species recorded as medicinal (Kew, 2017)
15.9%of those species cited in a medicinal regulatory publication
1,372notifications on FDA’s public new-dietary-ingredient list since 1995
4botanical drugs approved by FDA, 2006 to 2023
At a glance
From all plants to regulated ones
Of 342,953 accepted vascular plant species, 28,187 have a recorded medicinal use and 4,478 appear in a medicinal regulatory publication.
How the species count narrows from all vascular plants to those cited by regulatorsKew data
World Checklist of Vascular Plants (342,953 accepted species, April 16, 2021); Kew State of the World's Plants 2017 and Medicinal Plant Names Services (28,187 medicinal species; 4,478 cited in a medicinal regulatory publication). The two counts come from different Kew sources and dates.Data table: the three counts
Species counts in the flow
Step
Species
Share of the step before
Accepted vascular plant species
342,953
–
Recorded as of medicinal use
28,187
8.2%
Cited in a medicinal regulatory publication
4,478
15.9%
You will learn
Read the medicinal-plant funnel from published counts and say what each step measures.
Explain why names, plant parts and chemistry make identity the first barrier.
Describe the new dietary ingredient (NDI) rule and what FDA's public notification list shows.
Compare the effort behind supplement, food-ingredient and drug evidence using sourced estimates.
Explain how the drug-first clause, patent limits, CITES and access-and-benefit-sharing narrow the field.
Walk one candidate through seven gates and find the first question that stops it.
The funnel
The evidence funnel
Fewer than one in six recorded medicinal species appears in any medicinal regulatory publication.
From accepted plant species to species named in a regulatory text, each step loses most of the one beforeKew data
Govaerts R et al. Sci Data 2021;8:215 (342,953 accepted species, April 16, 2021). Allkin B. Useful plants: medicines. In: Willis KJ, ed. State of the World's Plants 2017. Royal Botanic Gardens, Kew; 2017 (28,187; 4,478; c. 1,280 under CITES).Data and limits of the funnel
Step
Species
Share of previous step
Source
Accepted vascular plant species
342,953
–
World Checklist of Vascular Plants, April 16, 2021
Recorded as being of medicinal use
28,187
8.2%
Kew Medicinal Plant Names Services, 2017
Cited in a medicinal regulatory publication
4,478
15.9%
Kew, 2017
Medicinal species under CITES protection
c. 1,280
4.5% of medicinal species
Kew, 2017
Kew calls 28,187 “probably a very conservative figure.” A regulatory publication includes pharmacopoeias from many countries; being cited is not U.S. authorization. Species are not ingredients: one species can yield several parts and extracts. We found no verified count of U.S. pharmacopeial botanical monographs and do not show one.
Each year FDA receives thousands of label notifications, dozens of new-ingredient notifications and about twenty botanical drug applications to studyFDA data
FDA burden estimates: 90 FR 35694 (July 29, 2025) and 89 FR 2957 (January 17, 2024). Park JK et al. Ther Innov Regul Sci 2025;59:1129–1137 (739 botanical INDs, March 1984 to December 2020). Approvals: Drugs@FDA. Rates are per year; the units differ by row.Data for the yearly rates
Item
Count
Period
Per year
Structure/function notifications, 21 CFR 101.93
3,690
FDA annual estimate
3,690
New dietary ingredient notifications, 21 CFR 190.6
55
FDA annual estimate
55
Botanical INDs received by CDER
739
March 1984 to December 2020 (about 36.8 years)
≈20
Botanical drugs approved
4
2006 to 2023
0.22
Notes and sources
Each step counts something different, so read the ratio between steps, not the drop alone. The share at step k is fk = nk ÷ nk−1: 28,187 ÷ 342,953 = 8.2%, and 4,478 ÷ 28,187 = 15.9%.
Barrier 1 · Identity
One name, many species
Identity has to be settled before anything else, because one trade name can cover 15 species and one species can carry 15 names.
Names fan out both ways: “ginseng” covers 15 species, and a medicinal species has 15 alternative names on averageKew data
Allkin B, State of the World's Plants 2017, Kew (415,180 names in 143 databases and publications). Dots are counts, not named species. U.S. law narrows this name: a food is misbranded if represented as ginseng “unless it is an herb or herbal ingredient derived from a plant classified within the genus Panax” (21 U.S.C. 343(u)).
FDA investigators cited missing identity tests 66 times in fiscal 2025, up from 15 in fiscal 2023FDA data
U.S. FDA, Inspection observations, FY2022–FY2025 (Form 483 citations under 21 CFR Part 111), as tabulated on Competitive landscape.Data: Form 483 citations by fiscal year
Fiscal year
Identity test, 111.75(a)(1)(i)
Supplier qualification, 111.75(a)(2)(ii)(A)
All Part 111
FY2022
22
25
1,218
FY2023
15
18
1,173
FY2024
39
29
1,583
FY2025
66
45
1,938
Notes and sources
A notification must name a botanical by “the Latin binomial name, including the author” (21 CFR 190.6(b)(2)), and a supplement maker must run at least one identity test on each dietary ingredient (21 CFR 111.75(a)(1)(i)). Course 3 teaches the methods.
Barrier 2 · New dietary ingredients
New dietary ingredient notifications
With no official list of pre-1994 ingredients, each firm documents its own status, and FDA's public list holds 1,372 notifications.
Publicly listed NDINs ran between 2 and 93 a year, near FDA's planning estimate of 55FDA data
U.S. FDA, “List of NDINs 1995 to the Present” (spreadsheet downloaded October 23, 2026), counted by year of submission; 89 FR 2957 for the estimate. All ingredient types, not only botanicals.Data: NDINs listed by year of submission
Years
Notifications per year, in order
1995–2004
2, 8, 14, 19, 24, 31, 20, 53, 64, 43
2005–2014
57, 64, 73, 40, 47, 53, 49, 42, 33, 40
2015–2025
48, 60, 93, 42, 33, 54, 47, 33, 45, 59, 71
The list has 1,372 rows numbered up to 1,460 (first submission July 7, 1995; last listed February 11, 2026). Two rows have a typing error in the submission date and are left out of the yearly counts; nine rows dated 2026 are not shown. FDA lists “publicly displayable” notifications it has reviewed, without the type of response.
Explore the NDIN record FDA data
Interactive calculator Change the inputs and the result updates. An educational simulation with stated inputs.
Range summary, years y₀ to y₁N = Σ ny · mean = N ÷ years
Notifications listed537
Mean per year53.7
Median days to FDA's response68
Responses after day 756.9%
2016 to 2025: 537 notifications, a mean of 53.7 a year, against FDA's estimate of 3,690 structure/function notices a year (about 69 to 1).
Notifications by year; the selected range is darkerFDA data
Response time is the date of FDA's response minus the submission date in FDA's list.
Method, assumptions and limits
What it calculates
For the chosen calendar years: the number of notifications in FDA's public list, the mean per year, the median number of days from the listed submission date to FDA's response, and the share of responses dated more than 75 days after submission.
Equations
N = Σ ny; mean = N ÷ number of years; the median is the middle value of the sorted response times (the mean of the two middle values for an even count).
Variables and units
y0, y1: calendar years, 1995–2025 (if reversed they are swapped). Response time: days. Two rows whose response predates submission are excluded from response times.
What it does not establish
The list holds only publicly displayable notifications and does not record whether FDA objected. A response after day 75 can follow an amendment that set a new filing date (21 CFR 190.6(d)); it is not a measure of FDA delay.
Verification
Six ranges are checked against an independent count of the same spreadsheet.
References
U.S. FDA, Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list downloaded October 23, 2026); 21 CFR 190.6; 89 FR 2957; 90 FR 35694.
Notes and sources
A new dietary ingredient is one “not marketed in the United States before October 15, 1994” (FD&C Act § 413(d)). FDA states: “There is no authoritative list of dietary ingredients that were marketed in dietary supplements before October 15, 1994.” It held a public meeting on such a list on October 3, 2017. Details are on NDIN strategy.
The safety basis is the costly part. When a notification relies on history of use alone, FDA “generally recommends 25 years of widespread use to be the minimum” (final guidance, October 2026); otherwise toxicology studies fill the gap between historical and proposed intake.
The explorer opens on 2016–2025, when FDA's median response came on day 68. Set the range to 1995–2025 and the median is 71 days, the all-years figure on NDIN strategy.
Barrier 3 · Cost of evidence
What the evidence costs
Sourced estimates put a supplement notice in hours of paperwork and the evidence for a new drug in billions of dollars.
Preparation effort rises from under an hour to 180 hours; drug evidence costs millions per trial and billions per approvalFDA estimatesPeer-reviewed
90 FR 35694 (2025); 89 FR 2957 (2024); 91 FR 51834 (2026, proposed rule). Moore TJ et al. JAMA Intern Med 2018;178:1451–1457. DiMasi JA, Grabowski HG, Hansen RW. J Health Econ 2016;47:20–33 (2013 dollars). Dollar figures are for drugs in general, not botanicals.Data for the ladder
Item
Estimate
Basis
Structure/function notification
0.75 hours
FDA, 3,690 notices a year
NDI notification
20 hours
FDA, extracting and summarizing information already in the company's files
GRAS notice
180 hours
FDA preliminary regulatory impact analysis, August 2026
Pivotal efficacy trial
$19.0 million (median; IQR 12.2–33.1)
138 trials behind 59 drugs approved 2015–2016
Out-of-pocket R&D per approved new drug
$1,395 million
106 drugs from 10 firms; 2013 dollars
Capitalized R&D per approved new drug
$2,558 million
Same sample, 10.5% real cost of capital
Notes and sources
FDA's hour estimates cover preparing a submission from data the firm already holds; they exclude generating studies. Drug estimates capitalize spending to approval and absorb failures: C = Σ ct(1 + r)T−t, with ct the spending in year t, T the approval year and r = 10.5% a year in DiMasi et al. Worked example: $1 spent ten years before approval counts as 1.10510 = $2.71 at approval.
Barrier 4 · The drug route
The botanical drug route
FDA received 739 botanical INDs from 1984 to 2020. Separately, it has approved four botanical drugs (2006–2023), each with a composition specification; the two counts cover different products and periods, so they are not an approval rate.
Most botanical INDs were allowed to proceed at 30 days, and about half were later withdrawn or terminatedFDA authors, peer-reviewed
Park JK, Lee D, Rui L, Gao X, Furness MS, Wu C. Ther Innov Regul Sci 2025;59(5):1129–1137, Table 1. Shares for “All” computed here from the counts.Data: botanical INDs by action and status
Category
Oncologic (254)
Non-oncologic (485)
All (739)
Safe to proceed at 30 days
175
282
457
Clinical hold at 30 days
56
111
167
Withdrawal at 30 days
12
14
26
Other initial actions
11
78
89
Active, December 2020
82
171
253
On hold, December 2020
7
33
40
Withdrawn or terminated
137
237
374
Inactive
24
31
55
Other status
4
13
17
Four plants, four drug substances, four approved usesFDA labels
Drugs@FDA (NDA 021902, NDA 202292, BLA 761192, NDA 215064) and the current labels, sections 1 and 11. Park et al. 2025 list these four as the approved botanical drugs.
Each approved botanical drug substance is specified as a mixture, down to constituents under 1%FDA labels
Section 11 (Description) of the Veregen, Filsuvez, NexoBrid and Mytesi labels, retrieved from the openFDA label database, October 23, 2026.Data: label specifications
Veregen: catechins 85 to 95% by weight of the drug substance, which “includes more than 55% of Epigallocatechin gallate (EGCg).”
NexoBrid: the listed proteins make up 80% to 95% w/w of anacaulase-bcdb.
Mytesi: average degree of polymerization of the oligomers 5 to 7.5.
Notes and sources
Half of those INDs had been withdrawn or terminated by December 2020. Three of the four approved products are applied to skin or wounds; crofelemer is the only oral one. A disease claim needs this route (Course 10). An ingredient approved or substantially investigated as a drug first can also be excluded from the supplement definition, § 201(ff)(3)(B); see Legal status.
Barrier 5 · Ownership and access
Patents and access rules
A plant as found in nature cannot be patented, and CITES and access-and-benefit-sharing rules govern who may collect and trade it.
CITES lists about 34,300 plant species, almost all in Appendix II; about 1,280 recorded medicinal species are among themCITES and Kew data
CITES Secretariat, “The CITES species,” counts as of February 23, 2023 (34,293 plant species, plus 4 subspecies and 13 varieties, 34,310 taxa in all; Appendix II includes 110 populations); CITES, “The CITES Appendices”; Kew, State of the World's Plants 2017; CBD Secretariat, list of Parties and “About the Nagoya Protocol,” read October 23, 2026.Notes and sources
The Supreme Court held that “A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated” (Myriad, 2013); Legal status covers what can be protected. The Nagoya Protocol entered into force on October 12, 2014 and has 143 Parties; the United States signed the Convention on Biological Diversity in 1993 but is not a Party.
For a U.S. firm the provider country's law still applies. Under the Protocol, utilization “includes research and development on the genetic or biochemical composition of genetic resources,” and access rules cover prior informed consent, mutually agreed terms and a permit or equivalent.
Barrier 6 · Variability
Batch-to-batch consistency
A natural mixture varies from batch to batch, so its effect has to be shown to be consistent.
Four lines of evidence named by FDA support consistent effect across batchesFDA guidance
FDA, Botanical Drug Development, Guidance for Industry, Revision 1 (December 2016), Section III.Notes and sources
FDA's botanical drug guidance names, as “one of the critical issues,” ensuring “that the therapeutic effect for marketed drug product batches is consistent,” supported by a “totality of the evidence” approach. The same variability affects supplement specifications; Course 5 explains its sources.
Putting it together
Barriers across stages
Most barriers bind at more than one stage, so solving them one at a time rarely clears a candidate.
Seven barriers across six development stagesEditorial assessment
Assessment by the course author from the rules cited on this page; not a measurement.Text version: why each barrier binds where it does
Identity binds at sourcing, characterization and filing (Latin binomial, 190.6(b)(2); identity test on each ingredient, 111.75).
Safety evidence binds where studies are run and where the notification states the basis for safety (190.6(b)(4)).
NDI status binds at filing; a process change can reopen it when FDA's draft view of “chemically altered” applies.
The drug-first exclusion binds at filing and marketing (§ 201(ff)(3)(B)).
Patent eligibility matters when a characterized form or process is to be protected (35 U.S.C. 101).
CITES and access rules bind at collection and at every shipment.
Variability binds wherever a lot is sourced, tested or scaled.
Notes and sources
For a product decision this sets the order of work. Identity and access come first because every later document depends on them; marketing history and the intended claim then decide whether the route is a notification, no filing, or a drug program, and so how much safety and clinical evidence to buy.
Explorer · Seven gates
One candidate, seven gates
Walking one candidate through seven gates shows where its route forks and where it stops.
The statutory clocks on the supplement and drug routesStatute and regulation
Interactive calculator Change the inputs and the result updates. An educational simulation with stated inputs.
Gates cleared7 of 7
Minimum wait before first sale75 days
RouteNDIN
Supplement route with a notification filed at least 75 days before marketing, then a structure/function notice within 30 days after.
Status of each gate for this candidateEducational logic
Identity: cleared
Access: cleared
Drug-first clause: cleared
Marketing history: new dietary ingredient
Food-supply exception: does not apply; NDIN required
Safety basis: cleared
Claim: structure/function statement
Method, assumptions and limits
What it does
Applies the order of questions on this page to one candidate and reports the route, the gates cleared, and the shortest statutory wait between filing and first interstate sale.
Rules used
Identity: 21 CFR 190.6(b)(2) and 111.75(a)(1)(i). Drug-first: § 201(ff)(3)(B). New dietary ingredient: § 413(d). Food-supply exception: § 413(a)(1). Notification 75 days before marketing: § 413(a)(2), 21 CFR 190.6. Structure/function notice within 30 days after: 21 CFR 101.93(a)(1). Disease claim: 21 CFR 101.93(g). IND in effect 30 days after receipt: 21 CFR 312.40(b).
Assumptions
“Believed so, no records” is planned as a new dietary ingredient, because FDA keeps no authoritative list. The 25-year figure is FDA's recommended minimum when history of use alone is relied on, a recommendation rather than a rule. “Chemically altered” follows FDA draft guidance and is left to counsel.
Valid range
One botanical ingredient intended for a U.S. dietary supplement. It does not cover conventional foods, cosmetics, state law, sanctions or import rules.
What it does not establish
It is a teaching aid, not legal advice or a safety conclusion. Counsel decides legal status; qualified laboratories and experts generate the evidence.
Verification
Six answer sets are checked against an independent implementation of the same rules and by test cases.
Notes and sources
Three statutory clocks frame the routes: 75 days before marketing for an NDIN, 30 days after for a structure/function notice, and 30 days from receipt before an IND takes effect.
Common misreadings
Seven easy confusions
Recorded medicinal use≠clinical proof of effect
Cited in a regulatory publication≠lawful to sell in the United States
An NDIN acknowledged without objection≠FDA approval or a finding of safety
FDA's public NDIN list≠every notification FDA received
FDA's preparation hours≠the cost of the studies behind a submission
A botanical IND≠an approved botanical drug
CITES Appendix II≠a trade ban
Key terms
Nine terms used in this course
Show the 9 key terms
Accepted species
The name a checklist treats as correct; synonyms point to it.
Dietary ingredient
A vitamin, mineral, botanical, amino acid, dietary substance, or their extracts and combinations (§ 201(ff)(1)).
New dietary ingredient
One not marketed in the United States before October 15, 1994.
NDIN
Premarket notification of a new dietary ingredient, filed at least 75 days ahead.
IND
Investigational new drug application, needed to study a product as a drug.
Botanical drug
A drug from plants, algae or macroscopic fungi, usually a mixture.
Drug-first exclusion
§ 201(ff)(3)(B): an article approved as a new drug, or authorized for investigation as one with substantial clinical investigations instituted and made public, before it was marketed as a supplement or food, cannot be a supplement.
Access and benefit-sharing
Consent, agreed terms and benefit-sharing for using genetic resources.
Capitalized cost
Spending carried forward to approval at a cost of capital.
Check your understanding
Five questions on the untapped territory
Kew's 4,478 species are “cited in a medicinal regulatory publication.” Are they authorized for sale in the United States?
No. The publications include pharmacopoeias and regulatory texts from many countries. U.S. status depends on the product category, the ingredient's marketing history and the claims.
A supplier says its root extract was “sold before 1994.” What does FDA expect?
FDA keeps no authoritative list, so the firm must document that a supplement containing the ingredient, or the ingredient for use in supplements, was marketed before October 15, 1994. Without records, plan for a notification.
FDA estimates 20 hours to prepare an NDIN. Why is that not the cost of the safety case?
FDA's estimate covers extracting and summarizing information already in the company's files. Toxicology studies, chemistry and history-of-use research come before that and are not counted.
Why does a botanical drug label specify constituents present at under 1%?
The drug substance is a mixture. Ranges for minor constituents help show that each batch matches the material tested, which supports consistent therapeutic effect.
A species is in CITES Appendix II. Can it be traded?
Yes, if the exporting country grants an export permit. Appendix II controls trade; Appendix I prohibits it unless the purpose of the import is not commercial.
Next, disease claims
Course 10 reads the statute, FDA's own examples and the botanical drug pathway, with a claim sorter.
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.
Ready to check what you take?
Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.